You are using an outdated browser. Please upgrade your browser to improve your experience and security.


Patient and caregiver resources for sAML and treatment with VYXEOS

It’s important to feel supported every step of the way while receiving secondary acute myeloid leukemia (sAML) treatment. The resources below may help answer questions you may have about treatment, financial reimbursement, and support groups for those in the sAML community.

Notes icon

Frequently asked questions (FAQs)

Explore our most frequently asked questions and learn more about VYXEOS (vix-e-ose).
Get answers.

Camera icon

sAML patient stories

Tim and John share their journeys from being diagnosed with secondary AML to their personal experiences with VYXEOS.
Watch now or share your own story with the AML community.

Notes icon

Resource library

We’re here for you. Download educational information and find support groups.
Find sAML support and resources.

Money icon

sAML patient support

Learn about financial reimbursement options with JazzCares.
Financial options.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.